Abcellera Biologics Inc (ABCL) Stock Analysis
Verdict: WATCH (do not buy)
ABCL's Phase 2 validation of ABCL635 and $740M cash cushion drive momentum, but $150M annual burn and 58x P/S valuation demand pullback entry.
Investment score: 58/100
Analysis as of
Is Abcellera Biologics Inc stock worth reviewing? AI model thesis
AbCellera offers high-upside exposure to AI-driven antibody discovery validated by positive Phase 2 ABCL635 data, but current stretched valuation (58.6x P/S) dictates a Hold rating pending consolidation.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 90/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Abcellera Biologics Inc opportunities and risks
What speaks for ABCL
- Positive Phase 2 trial results for lead drug ABCL635 in August 2026 validate internal pipeline transition
What speaks against ABCL
- High clinical binary risk for lead proprietary assets
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ABCL | n/a | 58.6x | n/a | 75.0% | -248.8% | -4.6% |
| ARCH.V | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.0% |
| SONA.CN | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.3% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.2% |
Frequently asked questions about Abcellera Biologics Inc (ABCL)
Is ABCL stock a good investment?
The cached TradeMates AI model rates Abcellera Biologics Inc as WATCH (do not buy) with an investment score of 58/100. AbCellera offers high-upside exposure to AI-driven antibody discovery validated by positive Phase 2 ABCL635 data, but current stretched valuation (58.6x P/S) dictates a Hold rating pending consolidation. This is algorithmic model output, not personal investment advice.
Is ABCL stock a buy?
The TradeMates model verdict for ABCL is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.